Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated to include more precise eligibility criteria for subjects in a clinical study involving Nivolumab, including specific laboratory values and age requirements. Additionally, the text has been revised to clarify the exclusion criteria for certain patient populations.SummaryDifference35%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe webpage has undergone significant content removal, particularly regarding the detailed background and objectives of a study on Nivolumab for treating Epstein-Barr Virus-related lymphoproliferative disorders. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference55%
- Check38 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 17, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check60 days agoChange DetectedThe webpage has updated its contact information and important dates, replacing an old phone number and removing outdated dates.SummaryDifference0.4%
- Check67 days agoChange DetectedThe page has updated its last update dates, reflecting a shift from late 2024 to early 2025. This indicates a significant refresh of the content timeline.SummaryDifference0.8%
Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.